Cintas (CTAS) PT Lowered to $167 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Cintas (CTAS) PT Lowered to $160 at Credit Suisse Following 2Q beat and Raise
December 21, 2018 7:51 AM ESTCredit Suisse analyst Kevin McVeigh lowered the price target on Cintas (NASDAQ: CTAS) to $160.00 (from $205.00) while maintaining a Neutral rating following the company's 2Q earnings report.
CTAS reported revenue and EPS of $1.72b and $1.76 that beat the Street's of $1.69/$1.70 estimates. The company also... More
